Quantum Genomics (France) Today
| ALQGC Stock | EUR 0.07 0 1.77% |
Performance12 of 100
| Odds Of DistressLess than 20
|
Quantum Genomics is selling at 0.0721 as of the 14th of December 2024; that is 1.77% down since the beginning of the trading day. The stock's last reported lowest price was 0.072. Quantum Genomics has about a 20 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. The performance scores are derived for the period starting the 14th of November 2024 and ending today, the 14th of December 2024. Click here to learn more.
Quantum Genomics Socit Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It is also developing QGC011 that is in pre-clinical phase to treat hypertension with combination therapy and QGC006 to optimize the treatment of hypertension with a monotherapy drug. The company has 34.53 M outstanding shares. More on Quantum Genomics SA
Moving against Quantum Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Quantum Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Quantum Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Quantum Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Vice President - Operations | JeanPhilippe Milon |
| Business Concentration | Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Quantum Genomics SA (ALQGC) is traded on Euronext Paris in France and employs 8 people. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Quantum Genomics's market, we take the total number of its shares issued and multiply it by Quantum Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Quantum Genomics operates under Biotechnology sector and is part of Health Care industry. The entity has 34.53 M outstanding shares.
Quantum Genomics SA has accumulated about 5.01 M in cash with (17.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Quantum Genomics Probability Of Bankruptcy
Ownership AllocationQuantum Genomics owns a total of 34.53 Million outstanding shares. Quantum Genomics holds 9.18 pct. of its outstanding shares held by insiders and 3.69 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Quantum Ownership Details
Quantum Genomics Risk Profiles
Although Quantum Genomics' alpha and beta are two of the key measurements used to evaluate Quantum Genomics' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 8.96 | |||
| Semi Deviation | 2.76 | |||
| Standard Deviation | 25.75 | |||
| Variance | 663.01 |
Quantum Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Quantum Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Quantum Genomics Corporate Management
Elected by the shareholders, the Quantum Genomics' board of directors comprises two types of representatives: Quantum Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quantum. The board's role is to monitor Quantum Genomics' management team and ensure that shareholders' interests are well served. Quantum Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quantum Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephane Cohen | Chief Officer | Profile | |
| Sarah MerlenBoulenger | Head Affairs | Profile | |
| Bruno Besse | Chief Officer | Profile | |
| Benot Gueugnon | VP Director | Profile |
Additional Tools for Quantum Stock Analysis
When running Quantum Genomics' price analysis, check to measure Quantum Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Quantum Genomics is operating at the current time. Most of Quantum Genomics' value examination focuses on studying past and present price action to predict the probability of Quantum Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Quantum Genomics' price. Additionally, you may evaluate how the addition of Quantum Genomics to your portfolios can decrease your overall portfolio volatility.